HEMATOLOGY ONCOLOGY INPATIENT PROGRESS NOTE
Hospital Day : 45

Chief Concern
61 year old female with progressive AML ( NPM1 and FLT3 + ) , now on day 41 s/p low dose Ara-C and sorafenib with day 21 BM showing 20 % blasts . Now day 19 s/p reinduction with decitabine / cytarabine , day 14 BM showing 2 % blasts . Hospital course most recently complicated by anemia requiring daily transfusion , concerns for GI bleed versus other blood loss .

Interval History
- - no acute events overnight
- - continues to report greenish stools poetically described as " the color of the darkest green trees , " but denies overt BRBPR or tarry black stools . No abdominal pain , hematemesis or other obvious sources of blood loss .
- - denies other complaints
- - was transfused 1 unit of pRBCs overnight , had magnesium repleted

Allergies
codeine
acetaminophen
aspirin
penicillins
sulfonamides
benzodiazepines
Valium
Ambien
traMADol
traZODone

Medications
Scheduled Medications
Acyclovir 400 mg tab Dose : 800 mg = 2 tab PO Q12 Hours
Aminocaproic acid soln ( conc 250 mg/mL ) Dose : 2 , 000 mg = 8 mL PO Q6 Hours
Bag balm oint 300 g Dose : 1 application Topical BID
Chlorhexidine gluconate 2 % topical cloth Dose : 1 application Topical QPM
Fluconazole 200 mg tab Dose : 200 mg = 1 tab PO Daily
levoFLOXacin 750 mg tab Dose : 750 mg = 1 tab PO QHS
Lidocaine 5 % patch Dose : 1 patch Transdermal Daily
Lidocaine Topical Patch REMOVAL Dose : 1 each REMOVE Q24 Hours
Magnesium sulfate Dose : 8 mEq = 1.97 mL IVPB Once
Nystatin powder 15 g Dose : 1 application Topical BID
Pantoprazole 40 mg inj Dose : 40 mg IV Q12 Hours

PRN Medications
Ben - Gay ( or equivalent ) cream 57 g Dose : 1 application Topical BID PRN
Calcium carb 500 mg chewtab ( 200 mg elem ) Dose : 500 mg = 1 tab Chew TID PRN
Camphor menthol 0.5 % lotion 222 mL Dose : 1 application Topical BID PRN
Cetirizine 10 mg tab Dose : 10 mg = 1 tab PO Daily PRN
Docusate 100 mg cap Dose : 100 mg = 1 cap PO BID PRN
Eszopiclone 3 mg tab Dose : 3 mg = 1 tab PO QHS PRN
Heparin Flush 100units / mL inj 5 mL ( syr ) Dose : 500 units = 5 mL IV On Call PRN
HydrOXYzine pamoate 25 mg cap Dose : 25 mg = 1 cap PO QID PRN
Hypromellose 0.4 % ophth 15 mL Dose : 1 drop ( s ) EYE - Both Q2 Hours PRN
Lanolin , hydrous lubricant 28 g Dose : 1 application Topical 5 Times Daily PRN
Lidocaine ( viscous ) 2 % soln 100 mL Dose : 5 mL Mucosal QID PRN
Lidocaine 2.5 % - prilocaine 2.5 % cream 5 g Dose : 1 application Topical Daily PRN
Menthol lozenge # 20 Dose : 1 lozenge Mucosal Q1 Hour PRN
Ondansetron 4mg / 2mL inj Dose : 8 mg = 4 mL IV Q8 Hours PRN
Ondansetron 8 mg tab Dose : 8 mg = 1 tab PO Q8 Hours PRN
Oxycodone 5 mg tab Dose : 5-10 mg PO Q3 Hours PRN
Prochlorperazine 5 mg tab Dose : 5-10 mg PO Q6 Hours PRN
Senna 8 . 6mg tab Dose : 17.2 mg = 2 tab PO QHS PRN
Sodium chloride 0.9 % inj 5 mL FLUSH ( syringe ) Dose : 5 mL IV On Call PRN
Zaleplon 5 mg cap Dose : 5 mg = 1 cap PO QHS PRN

Vitals
Date
Result
Last
MIN
- MAX
09/16/13 10:50
Temp C :
36.6
36.6
- 37.6
09/16/13 10:50
HR :
82
80
- 95
09/16/13 10:50
RR :
16
16
- 18
09/16/13 10:50
SBP Non - Inv :
116
101
- 149
09/16/13 10:50
DBP Non - Inv :
85
56
- 85
09/16/13 10:50 O2 Sat :
96 on Room air

Height : 156 ( cm ) 5 ' 1 " ( ft / in ) ( 08/02/2013 )
Admit Wt : 92.4 ( kg ) 203 ( lbs ) ( 08/02/2013 )
BMI : 38 ( kg / m2 ) ( 08/02/2013 )
Last Daily Wt : 85.1 ( kg ) 187 ( lbs ) ( 09/15/13 09:00 )
Previous Daily Wt : 85.8 ( kg ) 189 ( lbs ) ( 09/14/13 09:00 )

Physical Exam
GENERAL : pleasant , talkative , no acute distress , lying in bed , comfortable
NEURO : moving all extremities , awake and alert , no focal deficits
HEENT : moist mucous membranes
NECK : trachea midline
CHEST : symmetric chest expansion w / o accessory muscle use , clear to auscultation bilaterally
CARDIAC : regular , no murmurs / rubs / gallops
ABDOMEN : obese , soft , non-tender , non-distended , bowel sounds present
EXT : warm , well perfused
SKIN : few scattered excoriations on trunk , upper extremities and back
T / L / D : PICC

Laboratory Studies
RESULTS FROM TODAY
RESULTS FROM YESTERDAY

- - -
09/15/13 22:00


| - ICa - - -
| - ICa - - -
- - -
- - -
- - -
| - Ca - - -

135
103
15
| - Ca 8.2
- - - - - - - - - | - - - - - - - - - - - - - | - - - - - - - - - - - - < - - -
| - Mg - - -

- - - - - - - - - | - - - - - - - - - - - - - | - - - - - - - - - - - - < 112
| - Mg 1.7
- - -
- - -
- - -
| - Phos - - -

3.9
26
0.65
| - Phos 3.5


RESULTS FROM TODAY
RESULTS FROM YESTERDAY

- - -
09/15/13 22:00


- - -
| - PT - - -
8.5
| - PT - - -
- - - ] - - - - - - - - - - - - - - - - - - - - - - [ - - -
| - INR - - -
0.91 ] - - - - - - - - - - - - - - - - - - - - - - [ 60
| - INR - - -

- - -
| - PTT - - -
25
| - PTT - - -

Radiological Studies
CT Abdomen / Pelvis w / contrast ( 9/16/13 ) -
pending

Assessment / Plan
61 year old female with progressive AML ( NPM1 and FLT3 + ) , now on day 41 s/p low dose Ara-C and sorafenib with day 21 BM showing 20 % blasts . Now day 19 s/p reinduction with decitabine / cytarabine , day 14 BM showing 2 % blasts . Overall plan is for additional chemotherapy , likely prior to returning to Alaska . Hospital course most recently complicated by anemia requiring daily transfusion , concerns for GI bleed versus other blood loss .

# Persistent anemia requiring transfusion , concern for slow GI bleed versus occult abdominal bleed : Etiology uncertain . Other etiologies such as chemotherapy toxicity less likely given the magnitude ( needs 1 unit per day ) , DIC panel and hemolysis labs were negative . Post-transfusion hct and plts have showed appropriate increase .
- - CT abdomen / pelvis to look for occult source ; will also perform bedside FAST exam to evaluate for abdominal bleed
- - will recheck coags today to look for coagulopathy as contributor
- - continue aminocaproic acid 2 gm q6 hrs , continue transfusion thresholds of > 50 k
- - continue protonix 40 mg IV BID for possible GIB
- - defer GI consult while pt neutropenic / thrombocytopenic ( as she cannot have interventions )

# AML with pancytopenia : { Normal karyotype , NPM1 positive , FLT3 - ITD positive with allelic ratio 0.66 }
Treatment has been : 2 doses decitabine from 2 / 13 to 3 / 13 with GCSF support followed by 14 days of Low dose Ara-C ( 8 / 8 ) and sorafenib ( 8 / 9 ) initiated for 14 days , followed by AraC / decitabine ( date 1 = 8 / 29 ) . With these treatments she continued to have persistent abnl myeloid blasts on cytology / flow , but BM population has decreased from 75 to 20 % to 3 % after each treatment . Overall plan is for another course of chemotherapy with a goal of acheiving remission .
- - plan for day 21 BM ( 9 / 18 ) followed by potentially another chemo course
- - transfusion thresholds : hct > 26 , plts > 50
- - prophylaxis :
fluconazole PO
acyclovir ( treatment dose completed 8 / 20 )
levofloxacin ( switched from Vanc 8 / 21 )

Chronic medical problems :
# DM type II : BGs stable inpatient . Not on medications at home . SSI if needed

# FEN : No MIVF as patient tolerating PO . monitor and replete electrolytes as needed .
# Prophylaxis : SCDs and ambulation
# Code status : FULL
# Contacts : brother ( George ) 406-665 - 5634
# Dispo : provider in Alaska will be Dr. Ornis at Alaska Native Medical Center . Patient would like to continue to pursue aggressive therapy . PT recommending 24 hr supervision and use of FWW at all times .

Nicholas Mark , M.D.
PGY - 3 Internal Medicine
Pager 206-416 - 5095

ATTENDING STATEMENT :
I saw and evaluated the patient and agree with Dr. Mark 's note .


Date of Service : 09/16/2013

Today 's Date is : 09/16/2013